查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433551

異位性皮膚炎臨床試驗市場規模、佔有率、趨勢分析報告：按分子類型、試驗設計、試驗階段、地區和細分市場預測，2024-2030

Atopic Dermatitis Clinical Trials Market Size, Share & Trends Analysis Report By Molecule Type (Small molecules, Large Molecules), By Study Designs, By Study Phase, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

異位性皮膚炎臨床試驗市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，全球異位性皮膚炎臨床試驗市場預計將達到48.4億美元，2024年至2030年複合年成長率為11.1%。

生物技術和醫學的研究開拓、異位性皮膚炎盛行率的增加、製藥公司對開發新藥的投資增加、CRO 和贊助公司之間的合作和收購的增加、臨床研究的技術進步和異位性皮膚炎。皮膚炎產品管道的增加、全球化臨床試驗等是預測期內支持全球市場良好成長的一些因素。

創新和輕鬆進入診所是製藥公司的重要因素。此外，製藥和生物製藥公司越來越注重開發新藥。例如，美國FDA表示，幾種治療異位性皮膚炎的潛在療法將在未來幾年內推向市場。可能進入市場的生物製藥包括協和麒麟的locatinlimab、禮來的lebrikizumab、KeyMed Bioscience的CM310和Astra Zeneca的tozolakimab。因此，治療藥物管道的增加是增加市場成長的主要因素之一。

此外，異位性皮膚炎的盛行率不斷上升是推動市場成長的關鍵催化劑。異位性皮膚炎是一種慢性發炎皮膚病，在全球範圍內患病率顯著增加，影響所有年齡層的患者。根據《2022 年全球疾病負擔 (GBD)》報告，到 2022 年，大約 2.23 億人將患有異位性皮膚炎。其中 1 至 4 歲年齡層有 4,300 萬人。盛行率的快速增加迫切需要更有效、更有針對性的治療方案。因此，製藥公司、研究機構和醫療機構正在增加對臨床試驗的投資，以探索新的治療性介入。

此外，一些公司正專注於併購等無機策略舉措，以增強其在產業中的地位。例如，2022年3月，輝瑞宣布收購Arena Pharmaceuticals，這是一家臨床階段的公司，致力於開發針對包括異位性皮膚炎在內的多種發炎疾病的創新潛在治療方法。

異位性皮膚炎臨床試驗市場報告亮點

  • 由於越來越多的生技藥品正在滲透到異位性皮膚炎臨床試驗產業，到2023年，大分子將在分子類型上佔據壓倒性的佔有率，達到53.2%。
  • 由於大量採用介入試驗設計的臨床試驗，介入試驗在市場上佔據主導地位。
  • III期預計將在2023年佔據最高的市場佔有率。這是由於正在進行 III 期試驗的藥物數量不斷增加。此外，III期試驗的成本遠高於其他階段，佔了最大的市場佔有率。
  • 由於該地區異位性皮膚炎盛行率不斷上升、該地區主要市場參與者的存在、政府對優質醫療保健的支持以及報銷計劃的可用性等因素，北美在市場上佔據主導地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 異位性皮膚炎臨床試驗市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 異位性皮膚炎臨床試驗市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 異位性皮膚炎臨床試驗市場：依分子類型估算及趨勢分析

  • 2023 年和 2030 年分子類型市場佔有率
  • 細分儀表板
  • 按分子類型分類的全球異位性皮膚炎臨床試驗市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第5章 異位性皮膚炎臨床試驗市場：透過研究設計進行估算與趨勢分析

  • 2023 年和 2030 年按研究設計分類的市場佔有率
  • 細分儀表板
  • 按研究設計分類的全球異位性皮膚炎臨床試驗市場前景
  • 2018年至2030年市場規模、預測與趨勢分析

第6章 異位性皮膚炎臨床試驗市場：分階段估計與趨勢分析

  • 2023 年及 2030 年分階段市場佔有率
  • 細分儀表板
  • 全球異位性皮膚炎臨床試驗市場分階段展望
  • 2018年至2030年市場規模、預測與趨勢分析

第7章 異位性皮膚炎臨床試驗市場：區域估計與趨勢分析

  • 2023 年及 2030 年按地區分類的市場佔有率分析
  • 按地區分類的市場儀表板
  • 區域市場簡介
  • 2018年至2030年市場規模、預測與趨勢分析
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 公司/競爭對手分類
    • 創新者
    • 市場領導者
    • 新興企業
    • 2023 年公司市場佔有率分析
  • 公司簡介
    • Charles River Laboratories
    • Imavita
    • REPROCELL Inc.
    • Oncodesign services
    • BIOCYTOGEN
    • QIMA LTD
    • Novotech
    • Redoxis
    • Syneos Health
    • Hooke Laboratories, LLC
Product Code: GVR-4-68040-182-6

Atopic Dermatitis Clinical Trials Market Growth & Trends:

The global atopic dermatitis clinical trials market is expected to reach USD 4.84 billion by 2030 and expand at a CAGR of 11.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Advancements in biotechnology and medicine, growing prevalence of atopic dermatitis, increasing investments by pharmaceutical companies in the development of novel drugs, rising partnerships and acquisitions among CROs and sponsor companies, technological advancements in clinical research, growing pipeline of atopic dermatitis products, and globalization of clinical trials are few of the factors supporting the lucrative growth of the global market during the forecast period.

For pharmaceutical companies, innovation and easy access to clinics are critical factors. Furthermore, pharmaceutical and biopharmaceutical companies increasingly focus on developing novel drugs for treating atopic dermatitis. For instance, the U.S. FDA stated that several potential therapeutics will be launched in the coming years to treat atopic dermatitis. A few of the potential biologics likely to enter the market include Rocatinlimab by -Kyowa Kirin Co., Ltd., lebrikizumab by Eli Lilly and Company, CM310 by Keymed Biosciences, tozorakimab by AstraZeneca and several others. Hence, the increasing pipeline of therapeutics is one of the major factors augmenting market growth.

Furthermore, the increasing prevalence of atopic dermatitis is a significant catalyst propelling the market growth. Atopic dermatitis is a chronic inflammatory skin condition that has witnessed a notable rise in incidence globally, affecting individuals of all ages. In 2022, approximately 223 million individuals are coping with atopic dermatitis, per the Global Burden of Disease (GBD) 2022 report. Among them, approximately 43 million falls within the age group of 1 to 4 years. This surge in prevalence has created a compelling need for more effective and targeted treatment options. As a result, pharmaceutical companies, research institutions, and healthcare organizations are increasingly investing in clinical trials to explore novel therapeutic interventions.

Moreover, several companies are focusing on inorganic strategic initiatives such as mergers and acquisitions to enhance their position in the industry. For instance, in March 2022, Pfizer Inc. announced the acquisition of Arena Pharmaceuticals, a clinical-stage company dedicated to developing innovative potential therapies for various immuno-inflammatory diseases, including atopic dermatitis.

Atopic Dermatitis Clinical Trials Market Report Highlights:

  • Large molecules dominated the molecule type segment with a 53.2% share in 2023 due to the increasing pipeline of biologics penetrating the atopic dermatitis clinical trials industry.
  • Interventional trials dominated the market owing to the large number of clinical trials with interventional study designs.
  • Phase III category by phase segment is anticipated to hold the highest market share in 2023. This is due to the increasing number of drugs undergoing phase III studies. Moreover, the cost of phase III studies is much higher than the other phases, contributing to the largest market share.
  • North America dominated the market owing to factors such as increasing the prevalence of atopic dermatitis in the region, presence of major market players in the region, government support for quality healthcare, and availability of reimbursement.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in North America
    • 1.5.2. Data for primary interviews in Europe
    • 1.5.3. Data for primary interviews in Asia Pacific
    • 1.5.4. Data for primary interviews in Latin America
    • 1.5.5. Data for Primary interviews in MEA
  • 1.6. Information or Data Analysis
    • 1.6.1. Data analysis models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis (Model 1)
    • 1.8.2. Approach 1: Commodity flow approach
    • 1.8.3. Parent Market Analysis (Model 2)
    • 1.8.4. Approach 2: Parent Market Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Primary Sources
  • 1.11. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of atopic dermatitis
      • 3.2.1.2. Growing pipeline of therapeutics
      • 3.2.1.3. Increasing funding and investments
    • 3.2.2. market restraint analysis
      • 3.2.2.1. High cost of clinical trials
      • 3.2.2.2. Issues in patient recruitment and retention
  • 3.3. Atopic Dermatitis Clinical Trials Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Atopic Dermatitis Clinical Trials Market: Molecule Type Estimates & Trend Analysis

  • 4.1. Molecule Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Atopic Dermatitis Clinical Trials Market by Molecule Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Small molecules
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Large Molecules
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Clinical Trials Market: Study Designs Estimates & Trend Analysis

  • 5.1. Study Designs Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Atopic Dermatitis Clinical Trials Market by Study Designs Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Interventional
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Observational
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Clinical Trials Market: Phase Estimates & Trend Analysis

  • 6.1. Phase Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Atopic Dermatitis Clinical Trials Market by Phase Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Phase I
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Phase II
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Phase III
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Phase IV
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Atopic Dermatitis Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Denmark
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Norway
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Thailand
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. Charles River Laboratories
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Imavita
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. REPROCELL Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Oncodesign services
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. BIOCYTOGEN
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. QIMA LTD
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Novotech
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Redoxis
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Syneos Health
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Hooke Laboratories, LLC
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 4 North America Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 5 North America Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 6 U.S. Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 8 U.S. Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 9 Canada Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 10 Canada Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 11 Canada Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 12 Europe Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 14 Europe Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 15 Europe Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 16 UK Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 17 UK Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 18 UK Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 19 Germany Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 20 Germany Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 21 Germany Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 22 France Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 23 France Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 24 France Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 25 Italy Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 26 Italy Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 27 Italy Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 28 Spain Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 29 Spain Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 30 Spain Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 31 Denmark Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 33 Denmark Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 34 Sweden Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 36 Sweden Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 37 Norway Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 38 Norway Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 39 Norway Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 44 Japan Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 45 Japan Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 46 Japan Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 47 China Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 48 China Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 49 China Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 50 India Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 51 India Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 52 India Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 53 Australia Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 54 Australia Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 55 Australia Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 56 Thailand Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 57 Thailand Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 58 Thailand Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 59 South Korea Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 61 South Korea Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 62 Latin America Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 65 Latin America Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 66 Brazil Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 67 Brazil Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 68 Brazil Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 69 Mexico Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 70 Mexico Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 71 Mexico Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 72 Argentina Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 73 Argentina Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 74 Argentina Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 75 MEA Atopic Dermatitis Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 77 MEA Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 78 MEA Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 79 South Africa Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 80 South Africa Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 81 South Africa Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 85 UAE Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 86 UAE Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 87 UAE Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Atopic Dermatitis Clinical Trials market, by molecule type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Atopic Dermatitis Clinical Trials market, by study designs, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Atopic Dermatitis Clinical Trials market, by phase, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Atopic Dermatitis Clinical Trials market: market outlook
  • Fig. 14 Atopic Dermatitis Clinical Trials competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Atopic Dermatitis Clinical Trials market driver impact
  • Fig. 20 Atopic Dermatitis Clinical Trials market restraint impact
  • Fig. 21 Atopic Dermatitis Clinical Trials market: Molecule Type movement analysis
  • Fig. 22 Atopic Dermatitis Clinical Trials market: Molecule Type outlook and key takeaways
  • Fig. 23 Small molecules market estimates and forecast, 2018 - 2030
  • Fig. 24 Large Molecules market estimates and forecast, 2018 - 2030
  • Fig. 25 Atopic Dermatitis Clinical Trials Market: Study Designs movement Analysis
  • Fig. 26 Atopic Dermatitis Clinical Trials market: Study Designs outlook and key takeaways
  • Fig. 27 Interventional market estimates and forecasts,2018 - 2030
  • Fig. 28 Observational market estimates and forecasts,2018 - 2030
  • Fig. 29 Atopic Dermatitis Clinical Trials Market: Phase movement Analysis
  • Fig. 30 Atopic Dermatitis Clinical Trials market: Phase outlook and key takeaways
  • Fig. 31 Phase I market estimates and forecasts,2018 - 2030
  • Fig. 32 Phase II market estimates and forecasts,2018 - 2030
  • Fig. 33 Phase III market estimates and forecasts,2018 - 2030
  • Fig. 34 Phase IV market estimates and forecasts,2018 - 2030
  • Fig. 35 Global Atopic Dermatitis Clinical Trials market: Regional movement analysis
  • Fig. 36 Global Atopic Dermatitis Clinical Trials market: Regional outlook and key takeaways
  • Fig. 37 Global Atopic Dermatitis Clinical Trials market share and leading players
  • Fig. 38 North America market share and leading players
  • Fig. 39 Europe market share and leading players
  • Fig. 40 Asia Pacific market share and leading players
  • Fig. 41 Latin America market share and leading players
  • Fig. 42 Middle East & Africa market share and leading players
  • Fig. 43 North America, by country
  • Fig. 44 North America
  • Fig. 45 North America market estimates and forecasts, 2018 - 2030
  • Fig. 46 U.S.
  • Fig. 47 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 48 Canada
  • Fig. 49 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 50 Europe
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 52 UK
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany
  • Fig. 55 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 56 France
  • Fig. 57 France market estimates and forecasts, 2018 - 2030
  • Fig. 58 Italy
  • Fig. 59 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 60 Spain
  • Fig. 61 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 62 Denmark
  • Fig. 63 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 64 Sweden
  • Fig. 65 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 66 Norway
  • Fig. 67 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 68 Asia Pacific
  • Fig. 69 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 70 Japan
  • Fig. 71 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 72 China
  • Fig. 73 China market estimates and forecasts, 2018 - 2030
  • Fig. 74 India
  • Fig. 75 India market estimates and forecasts, 2018 - 2030
  • Fig. 76 Australia
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 78 Thailand
  • Fig. 79 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 80 South Korea
  • Fig. 81 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 82 Latin America
  • Fig. 83 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 84 Brazil
  • Fig. 85 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 86 Mexico
  • Fig. 87 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 88 Argentina
  • Fig. 89 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 90 Middle East and Africa
  • Fig. 91 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 92 South Africa
  • Fig. 93 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 94 Saudi Arabia
  • Fig. 95 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 96 UAE
  • Fig. 97 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 98 Kuwait
  • Fig. 99 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 100 Market share of key market players- Atopic Dermatitis Clinical Trials market